Jamie Stiff
Direktor/Vorstandsmitglied bei Inversago Pharma, Inc.
Ursprung des Netzwerks ersten Grades von Jamie Stiff
| Einheit | Art der Einheit | Industrie | |
|---|---|---|---|
BIOTECanada
 BIOTECanada BiotechnologyHealth Technology BIOTECanada serves as a national association for Canada's health, industrial and agricultural biotechnology sectors. The company was founded in 1986 and is headquartered in Ottawa, Canada.
18
| Private Company | Biotechnology | 18 |
Genesys Capital Partners, Inc.
 Genesys Capital Partners, Inc. Investment ManagersFinance Genesys Capital Partners Inc (Genesys Capital) is an independent venture capital firm founded in 2000 by Damian Lamb, Plumley and Kelly Holman. The firm is headquartered in Toronto.
12
| Private Company | Investment Managers | 12 |
Allostera Pharma, Inc.
 Allostera Pharma, Inc. Medical DistributorsDistribution Services Allostera Pharma Inc. is a biopharmaceutical company that has developed an entirely new class of drugs, called Allosteramers™. Allosteramers™ have three main properties: 1) they are “allosteric”, meaning they do not bind to the same site as traditional drugs, potentially providing better safety, efficacy and an entirely new set of patentable intellectual properties, 2) they can have predictable and consistent drug properties, and 3) they are designed to be orally available. Using its Module X technology platform, Allostera has developed a pipeline of seven novel Allosteramers™ against different targets primarily focused on inflammation and autoimmunity including APG2305, a drug inhibiting the IL23 receptor, one of the most important targets in the autoimmune disease field. APG2305 has demonstrated oral activity in animal models of autoimmune diseases.
10
| Extinct | Medical Distributors | 10 |
Veralox Therapeutics, Inc.
 Veralox Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Veralox Therapeutics, Inc. develops small molecule therapeutics that treat the underlying pathologies of thrombosis and type 1 diabetes. The company was founded by Jeffrey W. Strovel, David J. Maloney and Matthew B. Boxer and is headquartered in Frederick, MD.
8
| Holding Company | Pharmaceuticals: Major | 8 |
Giiant Pharma, Inc.
 Giiant Pharma, Inc. BiotechnologyHealth Technology Giiant Pharma, Inc. is a Canadian preclinical-stage biotech company that specializes in designing gut-restricted small molecule drug therapeutics with various biological targets in gastroenterology. The company is based in Montréal, Canada and was founded by Elizabeth Elizabeth Kwong. The company's proprietary precision delivery technology platform allows for the creation of tissue-specific drugs with improved tolerability and enhanced therapeutic effects. Giiant's first lead program, GT-2108, is a microbiota-activated PDE4 inhibitor prodrug. Maxime Ranger has been the CEO of the company since 2021.
6
| Holding Company | Biotechnology | 6 |
Inversago Pharma, Inc.
 Inversago Pharma, Inc. Pharmaceuticals: MajorHealth Technology Inversago Pharma, Inc. develops novel gastrointestinal drugs. The company was founded by Fran?ois Ravenelle in and is headquartered in Montreal, Canada.
6
| Subsidiary | Pharmaceuticals: Major | 6 |
EBT Medical, Inc.
 EBT Medical, Inc. Medical/Nursing ServicesHealth Services EBT Medical, Inc. develops disruptive neurostimulation therapies for pelvic health disorders. The firm’s services include pelvic floor disorders and overactive bladder. The company was founded by Paul Yoo and Sasha John in 2014 and is headquartered in Toronto, Canada.
4
| Holding Company | Medical/Nursing Services | 4 |
Unternehmensgrafik - zweiten Grades
Beziehungen zu mehreren Unternehmen
Unternehmensverbindungen über das persönliche Netzwerk von Jamie Stiff
| Unternehmen | Sektor | Verknüpfte Personen | Hauptposition |
|---|---|---|---|
MedImmune LLC
 MedImmune LLC BiotechnologyHealth Technology MedImmune LLC develops medicines for the prevention and treatment of infectious diseases such as cancer and immune system disorders. It offers solutions in the areas of monoclonal antibodies and vaccines for infection, oncology, respiratory disease and inflammation, cardiovascular diseases, and neuroscience. The company was founded by Wayne T. Hockmeyer in 1988 and is headquartered in Gaithersburg, MD. | Biotechnology | General Counsel Director/Board Member Corporate Officer/Principal | |
| Washington University in St. Louis | College/University | Undergraduate Degree Doctorate Degree | |
| THERATECHNOLOGIES INC. | Pharmaceuticals: Major | Chief Tech/Sci/R&D Officer Corporate Officer/Principal Corporate Officer/Principal | |
| ANTHERA PHARMACEUTICALS, INC. | Pharmaceuticals: Major | Director/Board Member Chairman | |
Biotechnology Innovation Organization
 Biotechnology Innovation Organization Miscellaneous Commercial ServicesCommercial Services Biotechnology Innovation Organization is the world's biotechnology organization, providing advocacy, business development and communications services for more than 1,200 members worldwide. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology technologies. Corporate members range from entrepreneurial companies developing a first product to Fortune 100 multinationals. also represent state and regional biotech associations, service providers to the industry and academic centers. | Miscellaneous Commercial Services | Director/Board Member Director/Board Member | |
Zymeworks BC, Inc.
 Zymeworks BC, Inc. BiotechnologyHealth Technology Zymeworks BC, Inc. is a clinical-stage biopharmaceutical company engaged in the discovery, development, and commercialization of biotherapeutics. Its product, ZW25 and ZW49, are a bispecific antibody that cans two non-overlapping epitopes. The company was founded by Anthony Fejes, J. Haig deB Farris, Nick Bedford, Ali Tehrani and Andrew S. Wright on September 8, 2003 and is headquartered in Vancouver, Canada. | Biotechnology | Chief Executive Officer Founder | |
| MILESTONE PHARMACEUTICALS INC. | Pharmaceuticals: Major | Director/Board Member Director/Board Member Director/Board Member | |
| REBUS HOLDINGS, INC. | Biotechnology | Corporate Officer/Principal Corporate Officer/Principal | |
Lumira Capital Investment Management, Inc.
 Lumira Capital Investment Management, Inc. Investment ManagersFinance Lumira Capital Investment Management is a Venture Capital firm, a subsidiary of Nordion (Canada),Inc. founded in 1989 by Tony Pullen. The firm is headquartered in Toronto. | Investment Managers | Private Equity Investor Private Equity Investor Private Equity Analyst | |
Novo Holdings AS (Denmark)
 Novo Holdings AS (Denmark) Financial ConglomeratesFinance Novo Holding A/S provides financial investments and manages the Novo Nordisk Foundation?s assets. It offers seed and venture capital to development stage companies and takes ownership positions in companies within life science and biotechnology. The company was founded on September 8, 1999 and is headquartered in Hellerup, Denmark. | Financial Conglomerates | Chief Investment Officer Private Equity Investor | |
| University of Oxford | College/University | Doctorate Degree Undergraduate Degree | |
| MACROGENICS, INC. | Pharmaceuticals: Major | Director/Board Member Corporate Officer/Principal | |
| ALNYLAM PHARMACEUTICALS, INC. | Pharmaceuticals: Major | Director of Finance/CFO Corporate Officer/Principal Private Equity Investor | |
| McGill University | College/University | Doctorate Degree Undergraduate Degree Corporate Officer/Principal Undergraduate Degree Doctorate Degree | |
BDC Venture Capital
 BDC Venture Capital Investment ManagersFinance BDC Venture Capital (BDC Venture Capital) is a venture capital firm founded in 1975. The firm is headquartered in Québec, Canada. | Investment Managers | Private Equity Investor Private Equity Investor | |
| Queen's University of Belfast | College/University | Masters Business Admin Masters Business Admin | |
| The Johns Hopkins University | College/University | Corporate Officer/Principal Undergraduate Degree | |
| University of British Columbia | College/University | Undergraduate Degree Doctorate Degree | |
| University of Toronto | College/University | Undergraduate Degree Graduate Degree | |
| University of Western Ontario | College/University | Undergraduate Degree Masters Business Admin | |
| University of Montréal | College/University | Graduate Degree Corporate Officer/Principal Doctorate Degree | |
Angiochem, Inc.
 Angiochem, Inc. Pharmaceuticals: MajorHealth Technology Angiochem, Inc. is a clinical-stage biotechnology company, which engages in the development of pharmaceutical drugs for brain diseases and brain-related disorders. It offers small molecules and biologics, for the treatment of central nervous system diseases including primary brain cancer, brain metastases, lysosomal storage diseases, and pain. The company founded by Richard Béliveau in 2003 and is headquartered in Montreal, Canada. | Pharmaceuticals: Major | Director/Board Member Chief Executive Officer | |
| Université Laval | College/University | Graduate Degree Doctorate Degree | |
Forbion Capital Partners Management Holding BV
 Forbion Capital Partners Management Holding BV Investment ManagersFinance Forbion Capital Partners Management Holding BV (Forbion) is a Netherlands-based venture capital firm which was founded by Bart Bergstein. Headquartered in Naarden, the firm specializes in late-stage and early-stage clinical development programs to optimize the commercial potential of their investee company's technologies. | Investment Managers | Private Equity Investor Private Equity Investor Private Equity Investor | |
| THALLION PHARMACEUTICALS INC. | Pharmaceuticals: Major | Director/Board Member Corporate Officer/Principal | |
BioQuebec
 BioQuebec BiotechnologyHealth Technology BioQuebec is the largest biotechnology and life sciences network in Quebec, Canada. The private company is based in Bromont, Canada. BioQuebec's 130 members include companies and organizations that operate at every level of the biotechnology and life sciences innovation chain, ranging from biotechs to pharmas, contract research organizations, venture capital firms, and support organizations. The Canadian company engages in governmental representation, business development, and partnerships to support the growth of Quebec's biotechnology and life sciences industry, which creates wealth and specialized jobs, is focused on innovation and marketing, and is dedicated to improving everyone's health and quality of life. BioQuebec's actions aim to make Quebec one of the industry's most significant and valuable players on the international stage. The company was founded in 1991 by Pierre Alary, and the CEO is Mario Lebrun. | Biotechnology | Director/Board Member Director/Board Member | |
Interface Biologics, Inc.
 Interface Biologics, Inc. Information Technology ServicesTechnology Services Interface Biologics, Inc. operates as a commercial stage privately held company that develops transformative biomedical polymer technologies to improve the safety and effectiveness of medical devices. It provides technologies to medical device manufacturers and drug companies. The company was founded by Paul J. Santerre in December 2001 and is headquartered in Toronto, Canada. | Information Technology Services | Chairman Chairman | |
Alethia Biotherapeutics, Inc.
 Alethia Biotherapeutics, Inc. Pharmaceuticals: MajorHealth Technology Alethia Biotherapeutics, Inc. discovers and develops therapeutic mAbs against highly-disease tissue specific novel clinically-relevant targets. The firm focuses on bone loss in acute disorders, invasive carcinomas and on cancer-associated epithelial-to-mesenchymal transition. The company was founded in 2002 by Mario Filion and Yves Cornellier and is headquartered in Montreal, Canada. | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
Amplyx Pharmaceuticals, Inc.
 Amplyx Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Amplyx Pharmaceuticals, Inc. develops broad-spectrum antifungal agents for the treatment of life-threatening fungal infections. The firm's compound APX001, shows broad-spectrum activity in animal models of invasive fungal infection by common species of Candida and Aspergillus. It develops oral and injectable anti-infective drugs, including protease inhibitors and antibiotics. The company was founded by André Marquis, Mitchell W. Mutz and Gerry Crabtree in 2006 and is headquartered in San Diego, CA. | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
GlaxoSmithKline LLC
 GlaxoSmithKline LLC Pharmaceuticals: MajorHealth Technology GlaxoSmithKline LLC engages in discovering, developing, and delivering medicines, vaccines, and other healthcare products. It offers prescription medicines that treat various diseases, including cancer, HIV/AIDS, depression, diabetes, high blood pressure, herpes, asthma, migraine, and heart diseases, as well as stomach and skin problems, infections, and flu. It also provides vaccines for children and adults; and over-the-counter products. The company was founded in 1929 and is headquartered in Philadelphia, PA. | Pharmaceuticals: Major | Corporate Officer/Principal Director/Board Member | |
Augurex Life Sciences Corp.
 Augurex Life Sciences Corp. Medical SpecialtiesHealth Technology Augurex Life Sciences Corp. develops biomarkers that transform patient clinical management. Its biomarkers substances in the body that inform patient conditions and assist with diagnosis, treatment and disease monitoring. The company’s first biomarker Extracellular 14-3-3eta protein, serves as a drug target for the potential treatment of rheumatoid arthritis (RA). Augurex Life Sciences was founded by Norma K. Biln and Anthony Marotta in October 2007 and is headquartered in Vancouver, Canada. | Medical Specialties | Director/Board Member Founder | |
Innovative Medicines Canada
 Innovative Medicines Canada Miscellaneous Commercial ServicesCommercial Services Innovative Medicines Canada manufactures medical and toilet products. The company was founded on April 23, 1914 and is headquartered in Ottawa, Canada. | Miscellaneous Commercial Services | Director/Board Member Director/Board Member | |
| OBSEVA SA | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
Numab Therapeutics AG
 Numab Therapeutics AG Miscellaneous Commercial ServicesCommercial Services Numab Therapeutics AG is a biopharmaceutical company, which engages in the development of cancer immunotherapy. Its focuses on creating multi-specific antibodies that enable the pursuit of novel therapeutic strategies. The company was founded by Oliver Middendorp, David Urech, and Peter Lichtlen in 2011 and is headquartered in Wadenswil, Switzerland. | Miscellaneous Commercial Services | Director/Board Member Director/Board Member | |
| Harvard Business School | College/University | Masters Business Admin Masters Business Admin | |
| PROFOUND MEDICAL CORP. | Medical Specialties | Director/Board Member Chairman Director/Board Member | |
Adapsyn Bioscience, Inc.
 Adapsyn Bioscience, Inc. BiotechnologyHealth Technology Adapsyn Bioscience, Inc. operates as a biotechnology company focussed on the discovery and development of novel medicines. The company was founded by Nathan Magarvey and is headquartered in Hamilton, Canada. | Biotechnology | Director/Board Member Chief Executive Officer | |
Amplitude Ventures
 Amplitude Ventures Investment ManagersFinance Amplitude Ventures is a venture capital firm. The firm was founded in 2018. It’s headquartered in Montreal, Canada. | Investment Managers | Founder Private Equity Investor | |
VectorY BV
 VectorY BV Miscellaneous Commercial ServicesCommercial Services VectorY BV is a biotech company based in Amsterdam, Netherlands, that is dedicated to developing transformative medicines for people with neurodegenerative diseases such as ALS, Huntington's, and Parkinson's. VectorY's platform combines the promise of precise therapeutic antibodies with one-time AAV-based delivery to the CNS, enabling long-lasting CNS treatment after a single administration using cutting-edge antibody, AAV, and manufacturing technologies. The Dutch company's unique in-house expertise in antibodies, AAV vectors, protein degradation, manufacturing, and neuroscience drives the rapid development of much-needed disease-modifying therapies for neurodegenerative diseases. The company was founded by Sander J. van Deventer and Pavlina Konstantinova, with Sander J. van Deventer serving as the CEO since incorporation. | Miscellaneous Commercial Services | Director/Board Member Chairman | |
Code Biotherapeutics, Inc.
 Code Biotherapeutics, Inc. BiotechnologyHealth Technology Code Biotherapeutics, Inc. is a next-generation gene therapy company based in Greater Philadelphia. The American company is focused on developing targeted non-viral gene therapies to treat serious and life-threatening genetic diseases. The company uses a novel multivalent synthetic DNA delivery platform called 3DNA, which overcomes many of the challenges associated with viral-based gene therapies. Code Biotherapeutics is advancing an internal pipeline focused on select rare disease programs and establishing partnerships to take forward programs in both rare and prevalent diseases. Code Biotherapeutics is supported by top-tier investors that believe in their work to drive discovery programs forward as they aim to deliver on the promise of their proprietary synthetic DNA-based, non-viral genetic medicines delivery platform. The company was founded by Brian P. McVeigh, who has been the CEO since incorporation. | Biotechnology | Director/Board Member Director/Board Member | |
| ZYMEWORKS INC. | Pharmaceuticals: Major | Chief Executive Officer Chief Executive Officer |
Statistik
International
| Kanada | 28 |
| Vereinigte Staaten | 16 |
| Vereinigtes Königreich | 3 |
| Schweiz | 3 |
| Dänemark | 2 |
Sektoral
| Health Technology | 28 |
| Consumer Services | 12 |
| Finance | 7 |
| Commercial Services | 6 |
| Technology Services | 2 |
Operativ
| Director/Board Member | 294 |
| Corporate Officer/Principal | 110 |
| Chairman | 57 |
| Independent Dir/Board Member | 55 |
| Private Equity Investor | 52 |
Am stärksten vernetzte Beziehungen
| Insiders | |
|---|---|
| Ed Mathers Mathers | 47 |
| Ken Galbraith | 30 |
| Nanna Liebach Lüneborg | 29 |
| Maha Katabi | 28 |
| Stuart J. M. Collinson | 25 |
| Jean-François Pariseau | 24 |
| Jack Patrick Cashman | 19 |
| Alex Martin Martin | 19 |
| Jean-Paul Castaigne | 18 |
| Gordon McCauley | 18 |
| Marie Lindner | 18 |
| Christopher Henney | 18 |
| Peter Young | 15 |
| Marco Boorsma | 15 |
| Carlo Incerti | 14 |
- Börse
- Insiders
- Jamie Stiff
- Unternehmensverbindungen